STAAR Surgical Company (STAA)

Sep 25, 2026

Staar Surgical's stock rose 6% after the company's board of directors authorized a $50 million share repurchase program. CEO Warren Foust cited confidence in the company's business progress, strong balance sheet, and ample free cash flow, noting Staar has no outstanding debt and $181.5 million in cash and investments. The news led to a 6.3% increase in share price, bringing its market cap to $1 billion.

Sep 24, 2026

STAAR Surgical Company (NASDAQ:STAA) shares rose after announcing a $50 million share repurchase program authorized by its Board of Directors. The medical device company plans to fund the repurchases using organic free cash flow and cash on hand, reflecting confidence in its business and balance sheet strength. The program is expected to continue over the next twelve months, with the timing and amount determined at the company's discretion.

Sep 23, 2026

Levi & Korsinsky, LLP has launched an investigation into STAAR Surgical Company (NASDAQ: STAA) regarding potential breaches of fiduciary duties by its officers and directors. Current shareholders of STAA are encouraged to request additional information about this investigation. The firm, specializing in securities litigation and financial fraud, represents investors nationwide and seeks to recover funds for aggrieved shareholders.

Sep 23, 2026

Levi & Korsinsky, LLP has launched an investigation into STAAR Surgical Company (NASDAQ: STAA) regarding potential breaches of fiduciary duties by its officers and directors. Current shareholders of STAA are encouraged to seek additional information or contact the firm to learn more about the ongoing investigation. The firm specializes in securities litigation and aims to recover damages for aggrieved investors.

Sep 23, 2026

Levi & Korsinsky, LLP has launched an investigation into STAAR Surgical Company (NASDAQ: STAA) regarding potential breaches of fiduciary duties by its officers and directors. Shareholders of STAA are encouraged to seek additional information about the ongoing inquiry. The firm specializes in securities litigation and represents investors nationwide.

Sep 22, 2026

Jefferies has maintained a "Buy" rating on Staar Surgical (STAA) but has lowered its price target to $23.00 from $28.00. This adjustment reflects a cautious outlook, despite GuruFocus indicating the stock is 37.9% undervalued with a GF Value™ of $33.37. Investors are advised to exercise caution due to the company's high P/E ratio and the "Possible Value Trap" label.